A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals

Teja Muralidhar Kalidindi¹, Sang-Gyu Lee¹, Katerina Jou¹, Goutam Chakraborty², Myrto Skafida³, Scott T. Tagawa^{4,5}, Neil H. Bander⁵, Heiko Schoder^{1,3}, Lisa Bodei^{1,3}, Neeta Pandit-Taskar^{1,3}, Jason S. Lewis^{1,3,6}, Steven M. Larson^{1,3,6}, Joseph R. Osborne^{3,†}, Naga Vara Kishore Pillarsetty^{1,6*}

¹Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

²Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

³Department of Radiology, Weill Cornell Medicine, New York, NY

⁴Department of Medicine, Weill Cornell Medicine, New York, NY

⁵Department of Urology, Weill Cornell Medicine, New York, NY

⁶Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY

*Corresponding Author:

Naga Vara Kishore Pillarsetty PhD
Department of Radiology
Memorial Sloan Kettering Cancer Center,
MSKCC Zuckerman building,
408 E 69th St, ZRC-2064, New York, NY 10065
E-mail: pillarsn@mskcc.org

†Co-corresponding Author:

Joseph Osborne, MD PhD
Department of Radiology
Weill Cornell Medicine
E-mail: jro7001@med.cornell.edu

Abstract:

The past five years have seen an increasing acceptance of peptide-based prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) agents for treatment of metastatic castration-resistant prostate cancer (mCRPC), with [^{177}Lu]-DKFZ-PSMA-617 ([^{177}Lu]-PSMA-617) emerging as the leading candidate. [^{177}Lu]-PSMA-617 and other PSMA ligands have shown efficacy in reducing the tumor burden in mCRPC patients but irradiation to salivary gland and kidneys is a concern and dose limiting factor. Therefore, methods to reduce non-target organ toxicity are needed to safely treat patients and preserve their quality of life. Here, we report the effects of the addition of the cold PSMA ligand DKFZ-PSMA-11 (PSMA-11) on the uptake of [^{177}Lu]-PSMA-617 in tumor, salivary glands and kidneys. Groups of athymic nude mice (n = 4) bearing PC3-PIP (PSMA+) tumor xenografts were administered with [^{177}Lu]-PSMA-617 along with 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11. Biodistribution studies 1 h post-administration revealed that [^{177}Lu]-PSMA-617 uptake in PSMA-expressing PC3-PIP tumors was 21.71 ± 6.13 , 18.7 ± 2.03 , 26.44 ± 2.94 , 16.21 ± 3.5 , 13.52 ± 3.68 , and 12.03 ± 1.96 %ID/g when 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11 were added, respectively. Corresponding kidney uptake values were 123.14 ± 52.52 , 132.31 ± 47.4 , 84.29 ± 78.25 , 2.12 ± 1.88 , 1.16 ± 0.36 , 0.64 ± 0.23 %ID/g, respectively. Corresponding salivary gland uptake values were 0.48 ± 0.11 , 0.45 ± 0.15 , 0.38 ± 0.3 , 0.08 ± 0.03 , 0.09 ± 0.07 , 0.05 ± 0.02 % ID/g, respectively. Thus, uptake of PSMA TRT agents in salivary gland and kidney can be substantially reduced without impact on tumor uptake by adding cold PSMA-11. Our data provides proof-of-concept and we

propose that similar strategy be pursued in future clinical trials to prevent xerostomia and renal toxicity arising from [^{177}Lu]-PSMA-617.

Introduction

In 2020, an estimated 192,000 new patients will be diagnosed with prostate cancer in US ¹, adding to the 3.6 million men who have been previously diagnosed with prostate cancer (PC). Of those new patients, 33,330 (~17%) will die from metastatic disease, despite the implementation of therapies such as androgen deprivation therapy (ADT), surgery, immunotherapy, chemotherapy and radiation therapy ¹. To overcome the limitations of current treatment strategies, researchers are developing novel therapies, including targeted radionuclide therapy (TRT) with therapeutic radionuclides (iodine-131, lutetium-177, actinium-225, thorium-227) appended to molecules that target PC cells or their microenvironment ². Prostate specific membrane antigen (PSMA), also known as folate hydrolase-1 (FOLH1), is an androgen receptor (AR)-regulated target gene that is highly overexpressed on the apical membrane of both localized and metastatic PC lesions, especially in non-responding patients ³. Transcriptomic analysis of tumor biopsy samples of PC patients clearly indicates that the expression of PSMA is upregulated at transcript level with the progression of disease (**Fig 1**) ⁴. Because PSMA is highly expressed in PC ⁵⁻⁷, provides an attractive target, and can even be used to treat lesions that stop responding to conventional therapies, it has become a subject of intense interest to the nuclear medicine clinical community, both as an imaging and a therapeutic agent.

The potential of PSMA as a target for imaging of prostate cancer was initially demonstrated with imaging agent [^{111}In]-Capromab Pendetide (Prostascint®) in 1996 ⁸. Independently, Bander's group developed the humanized monoclonal antibody J591, which targets the external epitope of PSMA. Imaging studies with radiolabeled J591 demonstrated its superiority over [^{111}In]- Prostascint® using PET and SPECT imaging techniques ^{9, 10}. J591 radiolabeled with therapeutic isotopes (^{90}Y , ^{177}Lu and ^{225}Ac) has demonstrated efficacy both in preclinical and clinical studies ^{11, 12}. However, due to the long plasma circulation time of the antibodies, a dose-limiting myelotoxicity was observed.

To circumvent the problems arising from the long plasma half-life of circulating mAbs, alternative PSMA-targeting agents with significantly shorter plasma half-life have been developed. These include small molecules ¹³, affibodies, minibodies ¹⁴, single chain fragments ^{15, 16}. Most of the small-molecule-based PSMA-targeting radiopharmaceuticals have a common glutamyl-urea-amino acid moiety (indicated in red in **Fig. 2**) as initially proposed by Pomper et. al. in 2005 ¹⁷. These radiopharmaceuticals bind to the catalytic site of PSMA with low nanomolar affinities; because of their low molecular weight (< 2000 Da) and hydrophilic nature, they rapidly clear from the blood pool. This results in substantially lower radiation doses to bone marrow/hematopoietic system can be achieved ¹⁸. This has led to the rapid clinical translation of many glutamyl-urea-amino acid derivatives both for diagnostic and therapeutic applications in prostate cancer ¹⁹. As of April 2020, a simple search in the clinicaltrials.gov website reveals more than 225 clinical trials on radiolabeled small molecules targeting PSMA in prostate and other cancers. While several different

agents are in clinical trials, the most widely studied include [^{68}Ga]-DKFZ-PSMA-11, [^{18}F]-DCPyFI, [^{131}I]-MIP-1095, [^{177}Lu]-DKFZ-PSMA-617, [^{225}Ac]-DKFZ-PSMA-617, [^{177}Lu]-PSMA-I&T ²⁰. The efficacy of these small molecule-based imaging agents, especially [^{68}Ga]-DKFZ-PSMA-11, in identifying metastatic disease foci has been established ²¹. Imaging studies with [^{68}Ga]-DKFZ-PSMA-11 revealed high uptake in tumors and moderate-to-high uptake in normal organs that express PSMA, including salivary and lacrimal glands, small bowel, and kidneys ³. On the therapeutic front, the first-in-human studies were performed using the radioiodinated derivatives [$^{124/131}\text{I}$]-MIP-1095 from the Heidelberg group ²². Targeting was assessed using PSMA PET/CT and SPECT imaging studies that indicated excellent tumor uptake, moderate uptake in liver and proximal intestine, and high uptake in salivary glands, lacrimal glands and kidneys is related to high expression of PSMA in these organs ²³. The mRNA and protein expression data from the human protein atlas website also confirms the presence of PSMA at varying levels in normal prostate, small bowel (duodenum), kidney and salivary glands ²⁴. Dosimetry estimates for [$^{124/131}\text{I}$]-MIP-1095 revealed that the tumors received doses up to 6.25 mSv/MBq. Apart from the tumor, the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq), with minimal radiation dose to the red marrow (0.37 mSv/MBq). More than 60% of patients demonstrated prostate-specific antigen (PSA) decline. Owing to high tumor uptake and background clearance [^{177}Lu]-DKFZ-PSMA-617 is currently in phase 3 clinical trial. Dosimetry studies revealed that tumors received on average 3.3 mGy/MBq, leading to > 50% decline in PSA in 55% of selected patients ²⁵. These findings led to the rapid expansion of the use of [^{177}Lu]-PSMA-617 in clinical trials as a salvage option for patients who had stopped responding

to traditional hormonal therapies, [^{223}Ra]-RaCl₂, chemotherapy and immunotherapy. Common toxic side effects included grade 1–2 dry mouth, transient nausea, and fatigue; grade 3–4 thrombocytopenia was observed rarely (< 15%). While no prospective study has been completed, retrospective reports of [^{225}Ac]-PSMA-617 demonstrate significant responses even in patients who are refractory to [^{177}Lu]-PSMA-617 therapy ²⁶. Although, myelotoxicity was mild, grade 1–2 xerostomia was commonly observed (87% of patients) ²⁵. This can be expected because salivary glands are one of the dose-limiting toxicity organs receiving a dose of about 1 Gy/GBq of [^{177}Lu]-PSMA-617 ²⁷. The other dose-limiting organ are kidneys, which receive a dose of about 0.5–0.6 Gy/GBq of [^{177}Lu]-PSMA-617 and in which mild grade 1–2 renal dysfunction is observed. The salivary gland toxicity and possible renal toxicity can limit the scope of usage of PSMA agents particularly when labelled with alpha-emitters, such as [^{225}Ac]-PSMA-617, despite their tremendous potential to improve and extend the lives of mCRPC patients. Therefore, there is a clear and urgent unmet need to develop methods that can minimize exposure to the salivary gland and kidney and ensure the success of PSMA targeted radiotherapies.

In our previously reported work with [^{68}Ga]-PSMA-11 in mice models, we observed that adding excess of the ligand DKFZ-PSMA-11 to the radiopharmaceutical [^{68}Ga]-PSMA-11 reduces the uptake of [^{68}Ga]-PSMA-11 in salivary glands and kidneys without significantly affecting the uptake in tumor ^{28, 29}. Addition of the ligand results in the reduction of the effective molar activity (EMA), which is defined as the activity of the targeted radiopharmaceutical divided by the total amount of the targeted agent (radiolabeled pharmaceutical + free ligand) in moles. This finding led us to hypothesize

that reducing the effective molar activity of the therapeutic radiopharmaceutical [^{177}Lu]-PSMA-617 could be used to reduce the accumulation of radiopharmaceutical in the salivary glands and kidneys, thereby decreasing non-target organ toxicity. In the current report, we present the results of our study on the uptake of [^{177}Lu]-PSMA-617 in the tumor, salivary gland and kidney of athymic nude mice bearing PC3-PIP xenografts as a function of reducing the effective molar activity of our radiopharmaceutical by addition of cold ligand PSMA-11.

Figure 1: PSMA mRNA levels in prostate cancer samples analyzed from the Yu prostate data set (4). A total of 112 samples including 23 normal prostate, 64 prostate carcinoma, and 25 metastatic prostate cancer samples were analyzed on Affymetrix U95A-C microarrays; 8603 gene transcripts were analyzed and the PSMA (FOLH1) mRNA expression data was plotted using Graphpad Prism. P value calculated by unpaired student t test. P-trends were analyzed by one-way ANOVA.

Figure 2: Representative structures of peptide-based PSMA-targeted radiopharmaceuticals currently being evaluated in several preclinical and clinical studies.

Methods

All starting materials, solvents, and reagents were purchased from commercial sources (Sigma Aldrich, Fisher Scientific, ABX or MedKoo Biosciences Inc.) and used without further purification. The radiochemical precursor DFKZ-PSMA-617 (catalog number 206934) was purchased from MedKoo Biosciences Inc. (Morrisville, NC) and dissolved in metal free water to achieve a concentration of 1 mg/mL and 5 μ L (5 μ L) was aliquoted in 1.5 mL microcentrifuge tubes and stored at -80 °C and used for complexation reactions. DFKZ-PSMA-11 (catalog number 9920) was obtained from ABX advanced biochemical compounds GmbH (Radeberg, Germany). DFKZ-PSMA-11 (PSMA-11) was dissolved in metal-free water to achieve a concentration of 1 mg/mL and used for reducing the effective molar activity. All solvents used for HPLC analysis and purification within this project were purchased from Fisher Scientific (HPLC grade). For radiosynthesis TraceSELECT™ grade sodium acetate was used. Water (>18.2 M Ω cm⁻¹ at 25 °C) was obtained from an Alpha-Q Ultrapure water system from Millipore (Bedford, MA) and used for purification and HPLC purposes. Optima® grade acetonitrile was purchased from Fisher Scientific (Hampton, NH) and was used for HPLC purposes. Trifluoroacetic acid was purchased from Sigma Aldrich. Purification cartridge Strata™-X (#8B-S100-TAK, 33 μ m Polymeric Reversed Phase C-18, 30 mg/1mL) and analytical HPLC column Luna (00G-4252-E0, 250 x 4.6 mm, 5 μ , 100 Å, C-18 (2) with TMS end capping) were purchased from Phenomenex (Torrance, CA). Lutetium-177 in the form of lutetium chloride (¹⁷⁷Lu-LuCl₃) was obtained from Missouri University Research Reactor (MURR, Columbia, MO). Radioactivity was measured using Wizard 2480 gamma counter (Perkin Elmer, Waltham, MA).

Cell Lines

PC3-PIP cells (PC3-PSMA-IRES-Puromycin; kindly provided by Dr. Martin Pomper – Johns Hopkins University, Baltimore MD) were maintained under RPMI+10%FCS (Fetal Calf Serum)+PS (Penicillin and Streptomycin) media, puromycin, penicillin-streptomycin and used for our current studies.

Prostate Cancer Xenograft model

PC3-PIP cells were grown in RPMI+10%FCS (Fetal Calf Serum)+PS (Penicillin and Streptomycin) media. 5 million cells were used per xenograft. The cells were prepared in 200 μ l for xenografts in a solution of media and Matrigel® in a 1:1 ratio and were injected subcutaneously. The mice were monitored weekly, and by Week 3 the tumors reached an average size of 200–300mm³, at which point they were used for the experiment.

Radiosynthesis

Lutetium-177 in the form of lutetium chloride (¹⁷⁷Lu-LuCl₃) was obtained from Missouri University Research Reactor (MURR, Columbia, MO). 30 μ L of 0.25 M sodium acetate buffer (pH 5.5) was added to a 1.5 mL Eppendorf tube containing 5 nmoles of DKFZ-PSMA-617 (5 μ l, 1 mM solution in water) and briefly vortexed. To the resulting solution, 0.7 μ L of [¹⁷⁷Lu]-LuCl₃ (1.5 mCi) was added, then centrifuged for 20 seconds (500 rpm) and heated to 95 °C for 30 min to yield crude [¹⁷⁷Lu]-DKFZ-PSMA-617. The reaction mixture was allowed to cool and loaded onto a C18 reverse-phase cartridge (Strata™-X cartridge; Cat No. 8B-S100-TAK, 33 μ m Polymeric Reversed Phase C-18, 30 mg/1 mL)

that was preconditioned with 1 mL of 95% ethanol followed by 2.5 mL of pure water. The cartridge was then rinsed with 0.5 mL of water to remove non-chelated [^{177}Lu]- LuCl_3 . The pure product (1.45 mCi) was eluted using 450 μL of 66% ethanol in 0.9% saline solution. The molar activity of the product was 0.29 mCi/nmole.

Animal Doses

For formulating doses with reduced effective molar activity, calculated amounts of PSMA-11 (1 mg/mL in water) were added to the formulation. About 1.45 μCi of [^{177}Lu]-DKFZ-PSMA-617 at specific activity of 0.29 mCi/nmole containing about 5 pmoles of PSMA-617 was used directly or diluted with PSMA-11. Individual doses of [^{177}Lu]-DKFZ-PSMA-617 containing 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11 were prepared to yield [^{177}Lu]-DKFZ-PSMA-617 with effective molar activities of 0.29, 0.145, 0.0138, 0.00287 0.00144 and 0.000723 mCi/nmole. Considering average mass of mice (25 g) this translates to 0, 0.2, 4, 20, 40 and 80 nmoles of PSMA-11/kg dose in addition to the standard [^{177}Lu]-DKFZ-PSMA-617 dose.

Biodistribution Studies

[^{177}Lu]-DKFZ-PSMA-617 (7.5 μCi , 2.75 MBq) containing 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11 was administered via tail vein to different cohorts ($n = 4$) of athymic nude mice bearing PC3-PIP xenografts. Activity and weights of the syringes were measured pre- and post-injection to calculated amount of administered radioactivity. The mice were sacrificed by CO_2 asphyxiation 1 h post-administration. Blood was

collected immediately post-sacrifice by cardiac puncture and collected in a pre-weighed tubes. Necropsy was performed to collect tumor (PC3-PIP), heart, lungs, liver, spleen, stomach, small intestine, large intestine, kidney, muscle bone, tail and salivary glands. The organs were washed with water, air dried, transferred into pre-weighed tubes and counted for radioactivity on gamma counter. For calculating administered dose, several standards were prepared and counted along with the organs. Total administered counts were determined based on the difference in weight before and after injection of the activity. The counts from the gamma-counter were divided by injected counts. For each sample obtained, count data was background- and decay-corrected and the tissue uptake was measured in units of percent injected dose per gram (%ID/g) by dividing tissue counts to total administered counts normalized to the weight of the tissue multiplied by 100.

RESULTS

Synthesis of [¹⁷⁷Lu]-DKFZ-PSMA-617

[¹⁷⁷Lu]-DKFZ-PSMA-617 was synthesized in high purity (> 97%) with minimum molar activity of 11.1 GBq/μmole (300 mCi/μmole). No attempts to improve molar activity were made as this was enough for the intended application.

Biodistribution Studies

Table 1 provides the results of our 1 h biodistribution study in mice bearing PC3-PIP tumors of radiopharmaceutical [¹⁷⁷Lu]-DKFZ-PSMA-617 (55.5 kBq, 1.5 μCi, 5 pmoles) with addition of 0, 5, 100, 500, 1000 and 2000 pmoles of DKFZ-PSMA-11. The total amount of the PSMA-targeting ligand is 5, 10, 105, 505, 1005 and 2005 pmoles,

resulting in formulation of effective molar activities of 0.29, 0.145, 0.0138, 0.00287, 0.00144 and 0.000723 mCi/nmol. As expected, when no PSMA-11 was added to the [^{177}Lu]-PSMA-617 we observed high uptake in PSMA-expressing PC3-PIP tumor and kidneys and small but significant uptake in salivary glands. As the effective molar activity of the formulation was progressively decreased by addition of PSMA-11, we observed significant reductions in uptake of the radiopharmaceutical in the kidneys and salivary glands. Uptake of [^{177}Lu]-PSMA-617 in PC3-PIP tumors was 21.71 ± 6.13 , 18.7 ± 2.03 , 26.44 ± 2.9 , 16.21 ± 3.5 , 13.52 ± 3.68 , and $12.03 \pm 1.96\%$ ID/g when 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11 was administered along with [^{177}Lu]-PSMA-617 — equivalent to effective molar activities of 0.29, 0.145, 0.0138, 0.00287, 0.00144 and 0.000723 mCi/nmol. Corresponding values in kidney were 123.14 ± 52.52 , 132.31 ± 47.4 , 84.29 ± 78.25 , 2.12 ± 1.88 , 1.16 ± 0.36 , $0.65 \pm 0.23\%$ ID/g, respectively. In the PSMA-expressing salivary gland the uptake values were 0.48 ± 0.11 , 0.45 ± 0.15 , 0.38 ± 0.3 , 0.08 ± 0.03 , 0.09 ± 0.07 , $0.05 \pm 0.02\%$ ID/g, respectively. Notably, adding 2000 pmoles of PSMA-11 to [^{177}Lu]-PSMA-617 (equivalent to reducing the effective molar activity by 166-fold — 0.29 to 0.000723 mCi/nmole) — lowered mean uptake value (%ID/g) in PSMA+ tumor by about 44.5%, whereas in the kidneys and salivary glands the reduction of effective molar activity by 166-fold lowered mean uptake values by about 99.5% and 89.5%, respectively. These trends can be easily visualized in the graph that plots uptake (%ID/g) trends on a log10 scale as a function of effective molar activity (**Fig 3**). These experiments establish the feasibility of significantly reducing the uptake of [^{177}Lu]-PSMA-617 in salivary glands and kidneys.

Table 1: Biodistribution data of [^{177}Lu]-DKFZ-PSMA-617 (5 pmoles) as a function of total ligand mass in athymic nude mice bearing PC3-PIP xenografts at 1 h post-administration.

[^{177}Lu]-DKFZ-PSMA-617 uptake in organs as function of effective molar activity at 1 h						
	0.29 mCi/nmole	0.145 mCi/nmole	0.0138 mCi/nmole	0.00287 mCi/nmole	0.00144 mCi/nmole	0.000723 mCi/nmole
Blood	0.36 ± 0.06	0.4 ± 0.08	0.5 ± 0.54	0.12 ± 0.06	0.11 ± 0.08	0.08 ± 0.08
Tumor	21.71 ± 6.13	18.7 ± 2.01	26.44 ± 2.94	16.21 ± 3.53	13.52 ± 3.68	12.03 ± 1.96
Heart	0.26 ± 0.14	0.32 ± 0.08	0.28 ± 0.34	0.04 ± 0.01	0.27 ± 0.28	0.03 ± 0.02
Lungs	0.78 ± 0.16	0.89 ± 0.34	0.66 ± 0.6	0.08 ± 0.03	0.2 ± 0.12	0.13 ± 0.13
Liver	0.19 ± 0.06	0.17 ± 0.05	0.25 ± 0.24	0.06 ± 0.01	0.09 ± 0.02	0.05 ± 0.02
Spleen	1.53 ± 0.88	1.72 ± 0.95	0.82 ± 0.77	0.09 ± 0.01	0.16 ± 0.14	0.05 ± 0.02
Stomach	0.11 ± 0.03	0.09 ± 0.04	0.45 ± 0.53	0.14 ± 0.17	0.03 ± 0.01	0.19 ± 0.31
S Intestine	0.19 ± 0.14	0.1 ± 0.02	0.6 ± 0.62	0.14 ± 0.07	0.08 ± 0.04	0.13 ± 0.15
L Intestine	0.07 ± 0.02	0.09 ± 0.05	0.25 ± 0.18	0.1 ± 0.07	0.05 ± 0.02	0.19 ± 0.25
Kidneys	123.1 ± 52.5	132.3 ± 47.4	84.3 ± 78.2	2.12 ± 1.88	1.16 ± 0.36	0.64 ± 0.23
Muscle	0.16 ± 0.08	0.13 ± 0.03	0.19 ± 0.13	0.05 ± 0.06	0.05 ± 0.02	0.02 ± 0.01
Bone	0.16 ± 0.12	0.33 ± 0.1	0.31 ± 0.15	0.11 ± 0.09	0.14 ± 0.16	0.18 ± 0.3
Tail	0.87 ± 0.32	0.74 ± 0.16	2.16 ± 2.57	0.44 ± 0.27	0.36 ± 0.24	0.33 ± 0.36
Salivary Glands	0.48 ± 0.11	0.45 ± 0.15	0.38 ± 0.3	0.08 ± 0.03	0.09 ± 0.07	0.05 ± 0.02

Uptake of [^{177}Lu]-PSMA617 in PC3-PIP tumor bearing mice at 1 h

Figure 3. The absolute uptake of [^{177}Lu]-PSMA-617 as a function of effective molar activity. The absolute uptake of [^{177}Lu]-PSMA-617 in important organs at 1 h post-administration was plotted as a function of total mass of ligand administered to the animal. ANOVA was applied to analyze statistically whether effective molar activity affects absolute uptake of [^{177}Lu]-PSMA-617. *P*-values for blood, tumor, kidney, and salivary glands were less than 0.001 and the *p*-value for muscle is 0.0145. After ANOVA, Dunnett's multiple comparison test was performed using %ID/g at 5 pmoles of ligand as a control to analyze at what ligand mass the values differ statistically from the control group. *P*-value was marked in each group as asterisk (* *p* < 0.05, ** *p* < 0.01, *** *p* < 0.005, **** *p* < 0.001). As shown in the figure, absolute uptake of [^{177}Lu]-PSMA-617 in kidney, blood, and salivary gland is statistically lower when the total ligand mass is 500 pmoles or greater.

Discussion

Small-molecule-based PSMA-targeted therapeutic radiopharmaceuticals have revolutionized the field of prostate cancer by providing treatment options to metastatic castration-resistant prostate cancer (mCRPC) patients who have exhausted all other treatment options. One agent ($[^{177}\text{Lu}]\text{-PSMA-617}$) is the object of a currently ongoing randomized phase III registration trial. Both retrospective analysis of treatment data and prospective trials with therapeutic agents such as $[^{131}\text{I}]\text{-MIP-1095}$, $[^{177}\text{Lu}]\text{-PSMA-617}$, and $[^{225}\text{Ac}]\text{-PSMA-617}$ have demonstrated significant therapeutic benefit in mCRPC patients ¹⁹. As intended, these small-molecule-based TRT agents targeting PSMA have proven able to reduce bone marrow toxicity ^{22, 25}. Although cases of bone marrow toxicity grade 1 or higher were observed in a subset of patients undergoing PSMA TRT, it is likely that the patients experienced these side effects because either their bone marrow had been impoverished from prior therapies and/or they had high bone disease burden, which results in higher radiation dose to normal marrow next to the diseased sites.

PSMA expression in salivary glands and kidneys, however, poses significant challenges to the development and implementation of PSMA-targeted therapies, particularly for future applications with alpha-emitters. As a result of PSMA expression, patients have experienced grade 1–4 salivary gland toxicity, depending on the type of therapeutic agent. As expected these effects were particularly severe in patients being treated with $[^{225}\text{Ac}]\text{-PSMA-617}$ ^{26, 30}, while patients treated with $[^{177}\text{Lu}]\text{-PSMA-617}$ experienced the

relatively milder grade 1-2 toxicities²⁵. This represents a serious setback because the therapeutic responses with [²²⁵Ac]-PSMA-617 have been remarkable even in mCRPC patients who failed to respond to [¹⁷⁷Lu]-PSMA-617²⁶. Though initial observations from several clinical studies indicated that renal toxicity has been mild to moderate with these agents^{27, 31}, due to the lack of specific binding or reuptake in the tubules, toxicity at later time points cannot be ruled out. Therefore, to ensure successful adoption of the small-molecule-based PSMA-targeted therapies, we must minimize non-target organ toxicity. Toward this goal, many groups have attempted to minimize radiation-induced damage to salivary glands, including monosodium glutamate co-administration³², sialendoscopy with dilatation, saline irrigation and steroid injections³³, and external cooling of salivary and parotid glands³⁴. Regrettably, none of these techniques were particularly successful, while many proved to be rather cumbersome for routine clinical applications.

Our finding — that reducing the effective molar activity of PSMA-targeted small-molecule radiopharmaceuticals results in reduced salivary gland and kidney uptake — occurred during our work with the PSMA-targeted imaging agent [⁶⁸Ga]-DKFZ-PSMA 11²⁸. Encouraged by our results, we repeated these studies with the PSMA-targeting therapeutic radiopharmaceutical [¹⁷⁷Lu]-DKFZ-PSMA-617³⁵. Since multiple PSMA TRT agents are being developed, including [¹³¹I]-MIP-1095, [¹⁷⁷Lu]-DKFZ-PSMA-617, [¹⁷⁷Lu]-PSMA-I&T, [²²⁵Ac]-DKFZ-PSMA-617, [¹⁷⁷Lu]-EB-PSMA-617, [¹³¹I]-MSK-PSMA1 etc., our goal was to develop a method that applies equally to all the therapeutics and diagnostics currently being developed^{7, 30, 35-38}. We reasoned that if we develop a method based on reducing molar activity by adding the specific cold ligand of the

radiopharmaceutical (e.g. PSMA-617, EB-PSMA-617, PSMA-I&T), then the optimization must be done for each ligand separately because they have different pharmacokinetics. Therefore, the mass effect for each ligand is likely to be different in tumor and other organs. This represents a huge burden, as approval agencies might request clinical safety and efficacy data for each ligand separately. A major advantage of using PSMA-11 as a diluent to reduce effective molar activity is that its safety profile is well-established (at least in μg amounts) and, most importantly, it is not immunogenic. In addition, it is not protected by intellectual property, unlike most PSMA-targeting ligands. Therefore, if successful, it will permit immediate, international adoption of the technology across all groups working with the various PSMA TRTs — without the need for approval from patent/license holders. As such, we decided to use PSMA-11 as a diluent to reduce the effective molar activity of our preparation.

The mass of the preparation of [^{177}Lu]-PSMA-617 administered to mice was in the range used for conducting clinical studies. Fendler et al. reported the results of [^{177}Lu]-PSMA-617 study with the preparation's molar activity being approximately 0.05 GBq/nmole (1.35 mCi/nmole) and Hoffman et al. used the [^{177}Lu]-PSMA-617 preparation at a molar activity of 0.10 GBq/nmole (2.7 mCi/nmole) for their clinical trials^{25, 27}. Both groups used no carrier-added lutetium-177 for the preparation of their radiopharmaceuticals and the dose administered was about 6 GBq. Thus, assuming the average human weight to be about 70 kg, the total amount of the [^{177}Lu]-PSMA-617 preparation administered was about 0.85 nmoles/kg (Hoffman et al.) to 1.7 nmoles/kg (Fendler et al.). Using carrier-added lutetium-177, the molar activity of our preparations was 0.01 GBq/nmole (0.3

mCi/nmole). We administered about 1.45 $\mu\text{Ci}/5$ pmoles, translating to 0.2 nmoles/kg. The masses of PSMA-11 added to the [^{177}Lu]-PSMA-617 doses were about 0, 0.2, 4, 20, 40 and 80 nmoles/kg. Based on the molecular weight of PSMA-11 (947 Da), this translates to 0, 0.189, 3.788, 18.94, 37.88 and 75.76 $\mu\text{g}/\text{kg}$, respectively. For a 70 kg man, the administered masses of PSMA-11, in addition to the masses from the [^{177}Lu]-PSMA-617 preparation, will be 0, 13.3, 265, 1326, 2652 and 5303 μg , respectively, which is easily achievable. Using these lowered specific activity preparations, we can substantially reduce the uptake in salivary glands and kidneys while maintaining uptake in tumors. The reductions are significant, and if found also in humans they would reduce the severity of side effects such as xerostomia or reduced renal function without compromising tumor uptake. We do realize that data on uptake activity at later time points are needed to concretely establish that the addition of PSMA-11 to the [^{177}Lu]-PSMA-617 formulation will reduce non-target organ dose while maintaining the total radiation dose delivered to the tumor. This is beyond the scope of the current manuscript and will be published in a follow-up study. With the reduced uptake in non-target organs, we can potentially treat patients at higher doses or multiple times without causing any serious side effects.

Precedents for such behavior have been observed with small-molecule as well as antibody-based radiopharmaceuticals in pre-clinical or clinical studies. In the pre-clinical studies with Somatostatin-receptor-targeting radiopharmaceuticals, Nicolas et. al. observed that reducing the molar activity by adding a non-radiolabeled ligand from 10 to 2000 pmoles (similar to our study) resulted in significantly reduced uptake of the

radiopharmaceutical in the pancreas, salivary gland and marrow without reducing uptake in the tumor xenografts in mice models ³⁹. In the clinical studies conducted with PSMA-targeting radiolabeled antibodies (J591) ⁹ or radiolabeled mini-bodies (IA2BM) ¹⁴, excess cold antibody was administered to minimize liver uptake and under these conditions tumor uptake was maintained even at low molar activities with minimal uptake in salivary glands or kidneys. The radiolabeled antibodies/minibodies were administered along with 10–50 mgs of cold unlabeled molecules, contributing up to 345 nmoles of mAbs (50 mg, average molecular weight 145,000 Da) or 650 nmoles of minibody (50 mg, molecular weight 80,000 Da) to reduce uptake in liver. Kidney uptake with antibodies and minibodies is low because the nephrons in the kidneys restrict the filtration of molecules greater than 60,000 Da in size ⁴⁰. Therefore, we are confident that we can successfully translate our findings to the clinic and improve the pharmacokinetic profile of PSMA TRTs and, ultimately, patient outcomes. With side effects in salivary glands and kidneys minimized, PSMA TRTs could completely alter the treatment landscape of PC, with possible adoption of TRT at earlier stages — even before hormonal and chemotherapy options have been exhausted.

Conclusions

We demonstrate that by reducing the effective molar activity of our [¹⁷⁷Lu]-PSMA-617 preparation by addition of cold ligand PSMA-11, we can minimize uptake of the radiopharmaceutical in the salivary glands and kidneys without affecting uptake in the tumor. Because we have reduced the effective molar activity by adding the closely related but non-identical ligand PSMA-11, we believe this method can be easily adapted

to several other small-molecule-based PSMA-targeted radiotherapies. Clinical studies are urgently needed to optimize the amount of cold ligand added and to confirm these observations in patients. This simple method has tremendous potential to benefit patients by significantly reducing the dose-limiting toxic side effects of PSMA-targeted therapies and improving outcomes while maintaining quality of life.

Acknowledgements

Funding support from NIH/NCI R01CA207645-0 (JO, NP), DoD PCRP Idea Award W81XWH-19-1-0536 (NP), NIH/NCI R35 CA232130 (JSL) grants is gratefully acknowledged. Technical and facility services provided by Center of Comparative Medicine & Pathology were supported in part by NIH Grant P30 CA008748.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA: a cancer journal for clinicians*. Jan 2020;70(1):7-30.
2. Kratochwil C, Haberkorn U, Giesel FL. Radionuclide Therapy of Metastatic Prostate Cancer. *Semin Nucl Med*. Jul 2019;49(4):313-325.
3. O'Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. *The Prostate*. Feb 1 2004;58(2):200-210.
4. Yu YP, Landsittel D, Jing L, Nelson J, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Jul 15 2004;22(14):2790-2799.
5. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. *Cancer research*. Jun 15 1997;57(12):2321-2324.
6. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. *The Prostate*. Mar 1 2003;54(4):249-257.
7. Kratochwil C, Giesel FL, Stefanova M, Benesova M, et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with

- 177Lu-Labeled PSMA-617. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Aug 2016;57(8):1170-1176.
8. Han M, Partin AW. Current Clinical Applications of the In-capromab Pendetide Scan (ProstaScint(R) Scan, Cyt-356). *Reviews in urology*. Fall 2001;3(4):165-171.
9. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. *Clin Cancer Res*. Dec 1 2015;21(23):5277-5285.
10. Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, et al. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. *EJNMMI research*. 2015;5:28.
11. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. *Clin Cancer Res*. Sep 15 2013;19(18):5182-5191.
12. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using Y-90- and Lu-177-labeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. *Clin Cancer Res*. Oct 1 2005;11(19):7195s-7200s.
13. Kiess AP, Banerjee SR, Mease RC, Rowe SP, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. *Q J Nucl Med Mol Im*. Sep 2015;59(3):241-268.

14. Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, et al. First-in-Human Imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Dec 2016;57(12):1858-1864.
15. Frigerio B, Morlino S, Luison E, Seregini E, et al. Anti-PSMA I-124-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. *J Exp Clin Canc Res*. Jul 23 2019;38.
16. Nawaz S, Mullen GED, Sunassee K, Bordoloi J, Blower PJ, Ballinger JR. Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a Ga-68-THP-scFv targeting the prostate-specific membrane antigen. *EJNMMI research*. Oct 25 2017;7.
17. Foss CA, Mease RC, Fan H, Wang Y, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. *Clin Cancer Res*. Jun 1 2005;11(11):4022-4028.
18. Rowe SP, Drzezga A, Neumaier B, Dietlein M, et al. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Oct 2016;57(Suppl 3):90S-96S.
19. Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. *J. Nucl. Med*. Oct 2016;57:79s-89s.

20. Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. *Semin Nucl Med*. Jul 2019;49(4):302-312.
21. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [Ga-68]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with F-18-FECH. *Eur J Nucl Med Mol I*. Jun 2012;39(6):1085-1086.
22. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. *Eur J Nucl Med Mol Imaging*. Jul 2014;41(7):1280-1292.
23. O'Keefe DS, Bacich DJ, Heston WDW. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. *The Prostate*. Feb 1 2004;58(2):200-210.
24. <https://www.proteinatlas.org/ENSG00000086205-FOLH1/tissue>.
25. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. *Lancet Oncol*. Jun 2018;19(6):825-833.
26. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, et al. 225Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. *J. Nucl. Med*. Dec 2016;57(12):1941-1944.
27. Fendler WP, Reinhardt S, Ilhan H, Delker A, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617

- therapy for metastatic castration-resistant prostate cancer. *Oncotarget*. Jan 10 2017;8(2):3581-3590.
28. Pillarsetty N, Kalidindi T, Carlin S, Easwaramoorthy B, et al. Effect of specific activity on the uptake of ⁶⁸Ga -DKFZ-PSMA11 in tumor and other organs. *J. Nucl. Med.* May 2016;57:2.
 29. Ahad A, Easwaroorthy B, Zhang HW, Pillarsetty N, et al. Cyclotron produced Ga-68 for PET imaging of prostate cancer. *J. Nucl. Med.* May 2018;59:2.
 30. Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, et al. (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. *Eur J Nucl Med Mol Imaging*. Jan 2019;46(1):129-138.
 31. Assadi M, Rezaei S, Jafari E, Rekabpour SJ, et al. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. *World J Nucl Med*. Jan-Mar 2020;19(1):15-20.
 32. Rousseau E, Lau J, Kuo HT, Zhang Z, et al. Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Dec 2018;59(12):1865-1868.
 33. Rathke H, Kratochwil C, Hohenberger R, Giesel FL, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing (225)Ac-PSMA-617 RLT. *Eur J Nucl Med Mol Imaging*. Jan 2019;46(1):139-147.

34. Yilmaz B, Nisli S, Ergul N, Gursu RU, Acikgoz O, Cermik TF. Effect of External Cooling on (177)Lu-PSMA Uptake by the Parotid Glands. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Oct 2019;60(10):1388-1393.
35. Kalidindi TM, Lee SG, Punzalan B, Veach D, et al. Effect of reducing specific activity of [177Lu]-DKFZ-PSMA617 on uptake in the tumor, salivary gland and kidney. *J. Nucl. Med.* May 1, 2020 2020;61(supplement 1):230.
36. Zang J, Fan X, Wang H, Liu Q, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. Jan 2019;46(1):148-158.
37. Heck MM, Tauber R, Schwaiger S, Retz M, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. Jun 2019;75(6):920-926.
38. Kishore PNV, Teja K, Gyu LS, M LS, S LJ, Inventors. Novel theragnostic agents for PSMA postive cancers. Provisional Patent Application PCT- 62/894,5942019.
39. Nicolas GP, Mansi R, McDougall L, Kaufmann J, et al. Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Sep 2017;58(9):1435-1441.
40. Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. *J Clin Pharmacol*. Jan 2012;52(1 Suppl):54S-62S.